Agios Pharmaceuticals (AGIO) Competitors $35.21 -0.86 (-2.38%) Closing price 04:00 PM EasternExtended Trading$34.90 -0.31 (-0.87%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGIO vs. ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, TLX, and AXSMShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Its Competitors Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Telix Pharmaceuticals Axsome Therapeutics Roivant Sciences (NASDAQ:ROIV) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends. Do analysts rate ROIV or AGIO? Roivant Sciences presently has a consensus target price of $17.50, indicating a potential upside of 62.94%. Agios Pharmaceuticals has a consensus target price of $58.60, indicating a potential upside of 66.43%. Given Agios Pharmaceuticals' higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media refer more to ROIV or AGIO? In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 5 mentions for Agios Pharmaceuticals and 0 mentions for Roivant Sciences. Agios Pharmaceuticals' average media sentiment score of 0.33 beat Roivant Sciences' score of 0.00 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Roivant Sciences Neutral Agios Pharmaceuticals Neutral Is ROIV or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,798.26% compared to Roivant Sciences' net margin of -225.71%. Agios Pharmaceuticals' return on equity of -2.75% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-225.71% -14.76% -13.69% Agios Pharmaceuticals 1,798.26%-2.75%-2.52% Which has more risk & volatility, ROIV or AGIO? Roivant Sciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Which has stronger valuation and earnings, ROIV or AGIO? Agios Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$29.05M251.33-$171.98M-$0.25-42.96Agios Pharmaceuticals$36.50M55.87$673.72M$11.243.13 Do institutionals & insiders believe in ROIV or AGIO? 64.8% of Roivant Sciences shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAgios Pharmaceuticals beats Roivant Sciences on 10 of the 16 factors compared between the two stocks. Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.09B$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.01%P/E Ratio3.137.5519.3119.89Price / Sales55.87284.29424.59117.07Price / CashN/A41.7026.2128.59Price / Book1.307.397.925.55Net Income$673.72M-$55.04M$3.17B$248.49M7 Day Performance5.86%3.01%2.18%5.37%1 Month Performance2.56%-0.21%1.25%6.63%1 Year Performance-17.44%4.48%33.90%21.20% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals3.9594 of 5 stars$35.21-2.4%$58.60+66.4%-15.5%$2.09B$36.50M3.13390ROIVRoivant Sciences1.5092 of 5 stars$11.27-1.1%$17.50+55.3%+1.8%$7.74B$29.05M-45.08860ELANElanco Animal Health2.334 of 5 stars$14.29flat$15.17+6.1%+3.0%$7.10B$4.44B19.319,000Analyst UpgradeRVMDRevolution Medicines4.557 of 5 stars$36.79-0.3%$67.58+83.7%-1.4%$6.88B$11.58M-9.20250LEGNLegend Biotech3.0389 of 5 stars$35.49+2.5%$76.20+114.7%-23.7%$6.36B$627.24M-60.152,609GRFSGrifols4.0726 of 5 stars$9.04+2.0%$10.30+13.9%+28.9%$6.09B$7.81B7.7323,822News CoverageAnalyst UpgradeTGTXTG Therapeutics3.8581 of 5 stars$35.99-2.0%$40.80+13.4%+95.7%$5.83B$329M149.96290NUVLNuvalent3.7278 of 5 stars$76.30-4.2%$119.60+56.7%+10.3%$5.72BN/A-17.3840LNTHLantheus4.4154 of 5 stars$81.86+0.5%$130.50+59.4%+0.4%$5.64B$1.53B23.26700TLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.41B$516.72M0.00N/AAXSMAxsome Therapeutics4.6727 of 5 stars$104.39+1.0%$172.33+65.1%+28.5%$5.09B$385.69M-18.09380 Related Companies and Tools Related Companies Roivant Sciences Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGIO) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGIO Stock Alerts